STAAR Surgical (NASDAQ:STAA) Shares Gap Down Following Analyst Downgrade

STAAR Surgical Company (NASDAQ:STAA)’s stock price gapped down prior to trading on Thursday after Wedbush lowered their price target on the stock from $40.00 to $37.00. The stock had previously closed at $25.41, but opened at $24.08. Wedbush currently has an outperform rating on the stock. STAAR Surgical shares last traded at $24.3950, with a volume of 272,086 shares.

STAA has been the subject of several other reports. Wall Street Zen lowered shares of STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. UBS Group began coverage on STAAR Surgical in a research report on Tuesday, July 28th. They set a “sell” rating and a $20.00 price target on the stock. Zacks Research raised STAAR Surgical from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 4th. Weiss Ratings upgraded STAAR Surgical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 25th. Finally, Wells Fargo & Company upped their price objective on STAAR Surgical from $16.00 to $25.00 and gave the stock an “equal weight” rating in a report on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $26.61.

Key STAAR Surgical News

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: STAAR Surgical reported second-quarter 2026 revenue of approximately $93.5 million, substantially above analyst expectations near $90.6 million and more than double the prior-year period. Earnings also improved significantly from last year’s loss, with reports citing quarterly EPS of $0.16 to $0.31 versus a year-ago loss. STAAR Surgical Reports Second Quarter 2026 Results
• Positive Sentiment: Management expects to end 2026 with well over $200 million in cash, supporting investments in growth and leaving the company with a strong liquidity position. STAAR also plans to shift all China-related supply to Switzerland, which could improve supply-chain control and reduce geopolitical or regional production risks over time. STAAR Surgical Cash and Supply-Chain Update
• Neutral Sentiment: The earnings call highlighted procedure demand and geographic sales mix as important factors for the remainder of the year. Investors are assessing whether growth is broad-based and sustainable across markets. STAAR Surgical Q2 2026 Earnings Call Transcript
• Negative Sentiment: Some coverage reported EPS of $0.16, below the consensus estimate of $0.22, even though revenue exceeded expectations. This apparent earnings miss—and differing reported EPS figures across financial outlets—may be driving profit-taking and uncertainty after the release. STAAR Surgical Q2 Earnings Reaction

Hedge Funds Weigh In On STAAR Surgical

Several institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp bought a new stake in STAAR Surgical in the second quarter worth $6,578,000. Amundi purchased a new stake in STAAR Surgical during the first quarter valued at about $305,000. American Capital Management Inc. grew its stake in shares of STAAR Surgical by 18.7% during the first quarter. American Capital Management Inc. now owns 878,035 shares of the medical instruments supplier’s stock valued at $16,419,000 after buying an additional 138,499 shares during the last quarter. Quantinno Capital Management LP bought a new position in shares of STAAR Surgical during the first quarter valued at about $1,109,000. Finally, Renaissance Technologies LLC increased its holdings in shares of STAAR Surgical by 257.7% in the first quarter. Renaissance Technologies LLC now owns 135,200 shares of the medical instruments supplier’s stock worth $2,528,000 after buying an additional 97,400 shares during the period. Institutional investors own 96.70% of the company’s stock.

STAAR Surgical Stock Performance

The company has a quick ratio of 4.31, a current ratio of 5.12 and a debt-to-equity ratio of 0.09. The company has a fifty day moving average price of $26.98 and a 200 day moving average price of $24.08. The stock has a market cap of $1.23 billion, a PE ratio of -57.48 and a beta of 1.26.

STAAR Surgical (NASDAQ:STAA) last issued its earnings results on Wednesday, May 13th. The medical instruments supplier reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.05. The company had revenue of $93.52 million during the quarter, compared to analysts’ expectations of $78.72 million. STAAR Surgical had a positive return on equity of 3.31% and a negative net margin of 7.24%.STAAR Surgical’s quarterly revenue was up 119.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.10) EPS. Analysts expect that STAAR Surgical Company will post 0.13 earnings per share for the current year.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.